Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 251

1.

Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.

Conradie F, Zorrilla C, Josipovic D, Botes M, Osiyemi O, Vandeloise E, Eley T, Child M, Bertz R, Hu W, Wirtz V, McGrath D.

HIV Med. 2011 Oct;12(9):570-9. doi: 10.1111/j.1468-1293.2011.00927.x. Epub 2011 May 16.

2.

Atazanavir pharmacokinetics with and without tenofovir during pregnancy.

Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS; IMPAACT 1026s Study Team..

J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):412-9. doi: 10.1097/QAI.0b013e31820fd093.

3.

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.

Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES study team..

AIDS. 2010 Aug 24;24(13):2019-27. doi: 10.1097/QAD.0b013e32833bee1b.

PMID:
20613461
4.

Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.

Kreitchmann R, Best BM, Wang J, Stek A, Caparelli E, Watts DH, Smith E, Shapiro DE, Rossi S, Burchett SK, Hawkins E, Byroads M, Cressey TR, Mirochnick M.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):59-66. doi: 10.1097/QAI.0b013e318289b4d2.

5.

The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.

von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, Haberl A.

J Antimicrob Chemother. 2008 Sep;62(3):579-82. doi: 10.1093/jac/dkn204. Epub 2008 May 13.

PMID:
18477709
6.

Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.

von Hentig N, Müller A, Rottmann C, Wolf T, Lutz T, Klauke S, Kurowski M, Oertel B, Dauer B, Harder S, Staszewski S.

Antimicrob Agents Chemother. 2007 Apr;51(4):1431-9. Epub 2007 Feb 12.

7.

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R.

AIDS. 2005 Apr 29;19(7):685-94.

PMID:
15821394
8.

Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.

Cardiello PG, van Heeswijk RP, Hassink EA, Srasuebkul P, Mahanontharit A, Samor TM, Worarien W, Beijnen JH, Hoetelmans RM, Ruxrungtham K, Cooper DA, Lange JM, Phanuphak P.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):464-70.

PMID:
11981362
9.

Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.

Lê MP, Mandelbrot L, Descamps D, Soulié C, Ichou H, Bourgeois-Moine A, Damond F, Lariven S, Valantin MA, Landman R, Faucher P, Tubiana R, Duro D, Meier F, Legac S, Bourse P, Mortier E, Dommergues M, Calvez V, Matheron S, Peytavin G.

Antivir Ther. 2015;20(5):507-13. doi: 10.3851/IMP2936. Epub 2015 Jan 20.

PMID:
25599649
10.

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

Le Tiec C, Barrail A, Goujard C, Taburet AM.

Clin Pharmacokinet. 2005;44(10):1035-50. Review.

PMID:
16176117
11.

Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.

Pham PA, Flexner C, Parsons T, Vasist L, Fuchs E, Carson K, Agarwala S, Barditch-Crovo P.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):201-5.

PMID:
17414932
12.

Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.

Gantner P, Koeppel C, Partisani M, Batard ML, Bernard-Henry C, Cheneau C, De Mautort E, Priester M, Muret P, Sueur C, Fafi-Kremer S, Rey D.

Scand J Infect Dis. 2014 Dec;46(12):838-45. doi: 10.3109/00365548.2014.947318. Epub 2014 Sep 17.

PMID:
25229167
13.

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW; AIDS Clinical Trials Group 5201 Study Team..

JAMA. 2006 Aug 16;296(7):806-14.

PMID:
16905786
14.

Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.

Karlström O, Josephson F, Sönnerborg A.

J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):417-22.

PMID:
17159658
15.

Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.

Tomaka F, Lefebvre E, Sekar V, Van Baelen B, Vangeneugden T, Vandevoorde A, Diego Miralles G.

HIV Med. 2009 May;10(5):318-27. doi: 10.1111/j.1468-1293.2008.00690.x. Epub 2009 Feb 5.

16.

Atazanavir: in pediatric patients with HIV-1 infection.

Deeks ED.

Paediatr Drugs. 2012 Apr 1;14(2):131-41. doi: 10.2165/11208550-000000000-00000. Review.

PMID:
22292486
17.

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D; CASTLE Study Team..

Lancet. 2008 Aug 23;372(9639):646-55. doi: 10.1016/S0140-6736(08)61081-8.

PMID:
18722869
18.

Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.

Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, Ruggeri M, Suter F.

AIDS. 2007 Nov 30;21(18):2409-15.

PMID:
18025877
19.

Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.

Gutierrez-Valencia A, Ruiz-Valderas R, Torres-Cornejo A, Viciana P, Espinosa N, Castillo-Ferrando JR, Lopez-Cortes LF.

Clin Infect Dis. 2014 Jan;58(2):268-73. doi: 10.1093/cid/cit693. Epub 2013 Oct 21.

PMID:
24145880
20.

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.

Zorrilla CD, Wright R, Osiyemi OO, Yasin S, Baugh B, Brown K, Coate B, Verboven P, Mrus J, Falcon R, Kakuda TN.

HIV Med. 2014 Jan;15(1):50-6. doi: 10.1111/hiv.12047. Epub 2013 Jun 3.

Supplemental Content

Support Center